Previous close | 2,250.00 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 2,400.00 x N/A |
Day's range | 2,250.00 - 2,250.00 |
52-week range | 1,776.00 - 2,250.00 |
Volume | |
Avg. volume | 1 |
Market cap | 227.74B |
Beta (5Y monthly) | 0.96 |
PE ratio (TTM) | 13.89 |
EPS (TTM) | 162.00 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
DaVita Inc. ( NYSE:DVA ) saw a double-digit share price rise of over 10% in the past couple of months on the NYSE. The...
Pilot Collaboration for Aquadex® Ultrafiltration Therapy for Adult Patients with Congestive Heart Failure is extended to August 31, 2024MINNEAPOLIS, June 06, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, today announced the extension of its pilot phase under its previously announced supply and collaboration agreement with DaVita Inc. (NYSE: DVA) until August 31, 2024. This p
Key Insights Using the 2 Stage Free Cash Flow to Equity, DaVita fair value estimate is US$119 DaVita's US$135 share...